Compare VHC & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | DTIL |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | 23 | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 123.0M |
| IPO Year | 1999 | 2019 |
| Metric | VHC | DTIL |
|---|---|---|
| Price | $18.67 | $5.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 15.5K | ★ 256.9K |
| Earning Date | 11-14-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $106,000.00 | ★ $698,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2020.00 | N/A |
| 52 Week Low | $3.68 | $3.61 |
| 52 Week High | $29.00 | $8.82 |
| Indicator | VHC | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 40.77 |
| Support Level | $18.13 | $4.70 |
| Resistance Level | $23.70 | $5.54 |
| Average True Range (ATR) | 1.89 | 0.40 |
| MACD | -0.63 | -0.01 |
| Stochastic Oscillator | 5.52 | 28.71 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.